MedTrace Logo

Durvalumab Alone or in Combination With Novel Agents in Subjects With NSCLC

NCT03822351 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 189

Last updated 2024-10-08

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to compare the clinical activity of durvalumab alone vs durvalumab in combination with novel agents. The overall study goal is early identification of novel durvalumab combinations that are more active than durvalumab alone in the treatment of patients with unresectable, Stage III NSCLC who have not progressed after cCRT.

Conditions

  • Stage III Non-small Cell Lung Cancer
  • Unresectable

Interventions

DRUG

Durvalumab + Oleclumab

Durvalumab + Oleclumab

DRUG

Durvalumab

Durvalumab

DRUG

Durvalumab + Monalizumab

Durvalumab + Monalizumab

Sponsors & Collaborators

  • MedImmune LLC

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-12-19
Primary Completion
2023-07-18
Completion
2023-07-18
FDA Drug
Yes

Countries

  • United States
  • Canada
  • France
  • Hong Kong
  • Italy
  • Poland
  • Portugal
  • Spain
  • Taiwan

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03822351 on ClinicalTrials.gov